What is PolyActiva?
PolyActiva is a specialized medical technology firm focused on the development of biodegradable implants designed for sustained drug delivery. The company's core innovation, the Prezia Sustained Drug Delivery Technology, provides a precise, controlled mechanism for administering medication, specifically targeting ophthalmic diseases such as glaucoma. By addressing the limitations of traditional eye drops and daily treatment regimens, PolyActiva aims to significantly enhance patient compliance and therapeutic outcomes. The company has recently demonstrated its technical viability through promising Phase 2 clinical data, which highlighted substantial reductions in intraocular pressure, validating the efficacy of its platform in real-world clinical settings.
How much funding has PolyActiva raised?
PolyActiva has raised a total of $36.9M across 3 funding rounds:
Series A
$1.6M
Series B
$9.5M
Series C
$25.8M
Series A (2011): $1.6M, investors not publicly disclosed
Series B (2013): $9.5M led by Medical Research Commercialisation Fund (MRCF)
Series C (2025): $25.8M supported by Brandon Capital and NRFC
Key Investors in PolyActiva
Brandon Capital
Brandon Capital Partners is a prominent venture capital firm specializing in the biomedical sector, providing essential support from early-stage seed investment to expansion capital for life science innovators.
NRFC
The National Reconstruction Fund Corporation is an Australian Government initiative that provides strategic debt and equity financing to high-value projects within priority sectors, including medical science.
Medical Research Commercialisation Fund (MRCF)
Operating as Brandon BioCatalyst, this fund is a leading life science investor in Australia and New Zealand, dedicated to transforming biomedical research into commercial medical products.
What's next for PolyActiva?
With the successful closure of this major enterprise-level funding, PolyActiva is poised to transition into the next phase of its clinical roadmap. The strategic allocation of this capital will likely prioritize the advancement of its lead candidates through late-stage clinical trials and the scaling of manufacturing capabilities to support future commercialization. As the company continues to refine its Prezia platform, the focus will shift toward regulatory engagement and establishing market presence in the competitive ophthalmic sector. Investors and industry stakeholders will be closely monitoring the firm's ability to translate its clinical successes into a scalable, long-term treatment solution for patients suffering from chronic vision-threatening conditions.
See full PolyActiva company page
